Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maria Azmanova has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Synthesis, Characterisation, and in vitro Cytotoxic Activity of Dithiocarbamato Glycoconjugate Half‐Sandwich Ruthenium and Osmium Complexes

    by Joan J. Soldevila‐Barreda, Andrea Pettenuzzo, Maria Azmanova, Laia Rafols, Amr A. A. Attia, Alexandru Lupan, Luca Ronconi, Nicolas P. E. Barry, Anaïs Pitto‐Barry

    The synthesis by transmetallation and in‐depth characterisation by IR spectroscopy of five half‐sandwich ruthenium and osmium dithiocarbamato isonipecotamide glycoconjugate complexes are presented herein. The evaluation of their in vitro cytotoxicity and of the zinc precursors’ in vitro cytotoxicity towards ovarian cancer (A2780 and A2780cisR) and normal prostate (PNT2) cells is reported. While the cytotoxicity of the compounds is rather limited, some selectivity is observed.


  • Open Access

    Anticancer Water‐Soluble Organoruthenium Complexes: Synthesis and Preclinical Evaluation

    by Maria Azmanova, Laia Rafols, Patricia A. Cooper, Colin C. Seaton, Steven D. Shnyder, Anaïs Pitto‐Barry

    The synthesis, characterisation, and evaluation of the in vitro cytotoxicity of five maleonitriledithiolate‐based ruthenium metal complexes bearing various phosphine ligands towards two ovarian cancer cell lines (A2780 and A2780cisR), one non‐small‐cell lung cancer cell line (H460) and one normal prostate cell line (PNT2) are presented herein. These 18‐electron complexes were designed with four water‐soluble phosphine ligands to increase the water‐solubility character of the corresponding electron‐deficient ruthenium complex which showed great in vitro promises, and triphenylphosphine for comparison. The complexes with triphenylphosphine‐3,3′,3′′‐trisulfonic acid and triphenylphosphine present similar cytotoxicity compared to the 16‐electron precursor, with equal cytotoxicity to both A2780 and A2780cisR. Hints at the mechanism of action suggest an apoptotic pathway based on reactive oxygen species (ROS) production. No toxicity was observed in preliminary in vivo pilot studies for these two complexes in subcutaneous A2780 and A2780cisR xenograft models, with some evidence of tumour growth delay.


  • Open Access

    Synthesis, Characterisation and In Vitro Anticancer Activity of Catalytically Active Indole-Based Half-Sandwich Complexes

    by Joan J. Soldevila-Barreda, Kehinde B. Fawibe, Maria Azmanova, Laia Rafols, Anaïs Pitto-Barry, Uche B. Eke, Nicolas P. E. Barry

    The synthesis, characterisation and evaluation of the in vitro cytotoxicity of four indole-based half-sandwich metal complexes towards two ovarian cancer cell lines (A2780 and A2780cisR) and one normal prostate cell line (PNT2) are presented herein. Although capable of inducing catalytic oxidation of NADH and able to reduce NAD+ with high turnover frequencies, in cells and in the presence of sodium formate, these complexes also strongly interact with biomolecules such as glutathione. This work highlights that efficient out-of-cells catalytic activity might lead to higher reactivity towards biomolecules, thus inhibiting the in-cells catalytic processes.


  • Preclinical Anticancer Activity of an Electron‐Deficient Organoruthenium(II) Complex

    by Joan J. Soldevila‐Barreda, Maria Azmanova, Anaïs Pitto‐Barry, Patricia A. Cooper, Steven D. Shnyder, Nicolas P. E. Barry

    Ruthenium compounds have been shown to be promising alternatives to platinum(II) drugs. However, their clinical success depends on achieving mechanisms of action that overcome Pt‐resistance mechanisms. Electron‐deficient organoruthenium complexes are an understudied class of compounds that exhibit unusual reactivity in solution and might offer novel anticancer mechanisms of action. Here, we evaluate the in vitro and in vivo anticancer properties of the electron‐deficient organoruthenium complex [(p‐cymene)Ru(maleonitriledithiolate)]. This compound is found to be highly cytotoxic: 5 to 60 times more potent than cisplatin towards ovarian (A2780 and A2780cisR), colon (HCT116 p53+/+ and HCT116 p53−/−), and non‐small cell lung H460 cancer cell lines. It shows no cross‐resistance and is equally cytotoxic to both A2780 and A2780cisR cell lines. Furthermore, unlike cisplatin, the remarkable in vitro antiproliferative activity of this compound appears to be p53‐independent. In vivo evaluation in the hollow‐fibre assay across a panel of cancer cell types and subcutaneous H460 non‐small cell lung cancer xenograft model hints at the activity of the complex. Although the impressive in vitro data are not fully corroborated by the in vivo follow‐up, this work is the first preclinical study of electron‐deficient half‐sandwich complexes and highlights their promise as anticancer drug candidates.


  • Anticancer Activity of Electron‐Deficient Metal Complexes against Colorectal Cancer in vitro Models

    by Maria Azmanova, Joan Soldevila‐Barreda, Hira Bani Hani, Rianne M. Lord, Anaïs Pitto‐Barry, Steven M. Picksley, Nicolas P. E. Barry

    An evaluation of the in vitro cytotoxicity of nine electron‐deficient half‐sandwich metal complexes towards two colorectal cancer cell lines (HCT116 p53+/+, HCT116 p53−/−) and one normal prostate cell line (PNT2) is presented herein. Three complexes were found to be equally cytotoxic towards both colorectal cancer cell lines, suggesting a p53‐independent mechanism of action. These complexes are 12 to 34× more potent than cisplatin against HCT116 p53+/+ and HCT116 p53−/− cells. Furthermore, they were found to exhibit little or no cytotoxicity towards PNT2 normal cells, with selectivity ratios greater than 50. To gain an insight into the potential mechanisms of action of the most active compounds, their effects on the expression levels of a panel of genes were measured using qRT‐PCR against treated HCT116 p53+/+ and HCT116 p53−/− cells, and cell‐cycle analysis was carried out.


  • Schizophrenia: synthetic strategies and recent advances in drug design

    by Maria Azmanova, Anaïs Pitto-Barry, Nicolas P. E. Barry

    Schizophrenia is a complex mental disorder. Current and emerging approaches for the treatment of schizophrenia are surveyed.